Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 162

1.

Antibody-Neutralized Reovirus Is Effective in Oncolytic Virotherapy.

Berkeley RA, Steele LP, Mulder AA, van den Wollenberg DJM, Kottke TJ, Thompson J, Coffey M, Hoeben RC, Vile RG, Melcher A, Ilett EJ.

Cancer Immunol Res. 2018 Sep 12. doi: 10.1158/2326-6066.CIR-18-0309. [Epub ahead of print]

PMID:
30209061
2.

White paper on microbial anti-cancer therapy and prevention.

Forbes NS, Coffin RS, Deng L, Evgin L, Fiering S, Giacalone M, Gravekamp C, Gulley JL, Gunn H, Hoffman RM, Kaur B, Liu K, Lyerly HK, Marciscano AE, Moradian E, Ruppel S, Saltzman DA, Tattersall PJ, Thorne S, Vile RG, Zhang HH, Zhou S, McFadden G.

J Immunother Cancer. 2018 Aug 6;6(1):78. doi: 10.1186/s40425-018-0381-3.

3.

Ad5NULL-A20: A Tropism-Modified, αvβ6 Integrin-Selective Oncolytic Adenovirus for Epithelial Ovarian Cancer Therapies.

Uusi-Kerttula H, Davies JA, Thompson JM, Wongthida P, Evgin L, Shim KG, Bradshaw A, Baker AT, Rizkallah PJ, Jones R, Hanna L, Hudson E, Vile RG, Chester JD, Parker AL.

Clin Cancer Res. 2018 Sep 1;24(17):4215-4224. doi: 10.1158/1078-0432.CCR-18-1089. Epub 2018 May 24.

PMID:
29798908
4.

The Immune System in Oncolytic Immunovirotherapy: Gospel, Schism and Heresy.

Vile RG.

Mol Ther. 2018 Apr 4;26(4):942-946. doi: 10.1016/j.ymthe.2018.03.007. Epub 2018 Mar 21. No abstract available.

PMID:
29573976
5.

Genetically modified lentiviruses that preserve microvascular function protect against late radiation damage in normal tissues.

Khan AA, Paget JT, McLaughlin M, Kyula JN, Wilkinson MJ, Pencavel T, Mansfield D, Roulstone V, Seth R, Halle M, Somaiah N, Boult JKR, Robinson SP, Pandha HS, Vile RG, Melcher AA, Harris PA, Harrington KJ.

Sci Transl Med. 2018 Jan 24;10(425). pii: eaar2041. doi: 10.1126/scitranslmed.aar2041.

6.

Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade.

Samson A, Scott KJ, Taggart D, West EJ, Wilson E, Nuovo GJ, Thomson S, Corns R, Mathew RK, Fuller MJ, Kottke TJ, Thompson JM, Ilett EJ, Cockle JV, van Hille P, Sivakumar G, Polson ES, Turnbull SJ, Appleton ES, Migneco G, Rose AS, Coffey MC, Beirne DA, Collinson FJ, Ralph C, Alan Anthoney D, Twelves CJ, Furness AJ, Quezada SA, Wurdak H, Errington-Mais F, Pandha H, Harrington KJ, Selby PJ, Vile RG, Griffin SD, Stead LF, Short SC, Melcher AA.

Sci Transl Med. 2018 Jan 3;10(422). pii: eaam7577. doi: 10.1126/scitranslmed.aam7577.

7.

Inhibitory Receptors Induced by VSV Viroimmunotherapy Are Not Necessarily Targets for Improving Treatment Efficacy.

Shim KG, Zaidi S, Thompson J, Kottke T, Evgin L, Rajani KR, Schuelke M, Driscoll CB, Huff A, Pulido JS, Vile RG.

Mol Ther. 2017 Apr 5;25(4):962-975. doi: 10.1016/j.ymthe.2017.01.023. Epub 2017 Feb 22.

8.

Socializing Individualized T-Cell Cancer Immunotherapy.

Vile RG.

Mol Ther. 2016 Aug;24(7):1170-3. doi: 10.1038/mt.2016.132. No abstract available.

9.

Oncolytic vaccinia virus as a vector for therapeutic sodium iodide symporter gene therapy in prostate cancer.

Mansfield DC, Kyula JN, Rosenfelder N, Chao-Chu J, Kramer-Marek G, Khan AA, Roulstone V, McLaughlin M, Melcher AA, Vile RG, Pandha HS, Khoo V, Harrington KJ.

Gene Ther. 2016 Apr;23(4):357-68. doi: 10.1038/gt.2016.5. Epub 2016 Jan 27.

10.

Mighty MyD88 in Health and Disease.

Pulido JS, Raja H, Vile RG, Salomao DR, Viswanatha DS.

Retina. 2016 Mar;36(3):429-31. doi: 10.1097/IAE.0000000000000921. No abstract available.

PMID:
26655610
11.

Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors.

Rajani KR, Vile RG.

Viruses. 2015 Nov 13;7(11):5889-901. doi: 10.3390/v7112914. Review.

12.

Widespread Non-Canonical Epigenetic Modifications in MMTV-NeuT Breast Cancer.

Felts SJ, Van Keulen VP, Hansen MJ, Bell MP, Allen K, Belachew AA, Vile RG, Cunningham JM, Hoskin TL, Pankratz VS, Pease LR.

Neoplasia. 2015 Apr;17(4):348-57. doi: 10.1016/j.neo.2015.02.006.

13.

Early diagnosis and successful treatment of paraneoplastic melanocytic proliferation.

Jansen JC, Van Calster J, Pulido JS, Miles SL, Vile RG, Van Bergen T, Cassiman C, Spielberg LH, Leys AM.

Br J Ophthalmol. 2015 Jul;99(7):943-8. doi: 10.1136/bjophthalmol-2014-305893. Epub 2015 Apr 23.

14.

Progress in clinical oncolytic virus-based therapy for hepatocellular carcinoma.

Jebar AH, Errington-Mais F, Vile RG, Selby PJ, Melcher AA, Griffin S.

J Gen Virol. 2015 Jul;96(Pt 7):1533-50. doi: 10.1099/vir.0.000098. Epub 2015 Feb 23. Review.

15.

How to train your oncolytic virus: the immunological sequel.

Vile RG.

Mol Ther. 2014 Nov;22(11):1881-4. doi: 10.1038/mt.2014.188. No abstract available.

16.

Trick and treat: Ambushing recurrent tumors before they get out of the door.

Boisgerault N, Vile RG.

Oncoimmunology. 2014 Jan 16;3:e27811. eCollection 2014.

17.

[Tumor relapse: what makes you stronger can kill you].

Boisgerault N, Vile RG.

Med Sci (Paris). 2014 Apr;30(4):355-7. doi: 10.1051/medsci/20143004006. Epub 2014 May 5. French. No abstract available.

18.

Dermal and conjunctival melanocytic proliferations in diffuse uveal melanocytic proliferation.

Pulido JS, Flotte TJ, Raja H, Miles S, Winters JL, Niles R, Jaben EA, Markovic SN, Davies J, Kalli KR, Vile RG, Garcia JJ, Salomao DR.

Eye (Lond). 2013 Sep;27(9):1058-62. doi: 10.1038/eye.2013.131. Epub 2013 Jun 21.

19.

Synergistic cytotoxicity of radiation and oncolytic Lister strain vaccinia in (V600D/E)BRAF mutant melanoma depends on JNK and TNF-α signaling.

Kyula JN, Khan AA, Mansfield D, Karapanagiotou EM, McLaughlin M, Roulstone V, Zaidi S, Pencavel T, Touchefeu Y, Seth R, Chen NG, Yu YA, Zhang Q, Melcher AA, Vile RG, Pandha HS, Ajaz M, Szalay AA, Harrington KJ.

Oncogene. 2014 Mar 27;33(13):1700-12. doi: 10.1038/onc.2013.112. Epub 2013 Apr 29.

20.

The efficacy versus toxicity profile of combination virotherapy and TLR immunotherapy highlights the danger of administering TLR agonists to oncolytic virus-treated mice.

Rommelfanger DM, Compte M, Diaz RM, Ilett E, Alvarez-Vallina L, Thompson JM, Kottke TJ, Melcher A, Vile RG.

Mol Ther. 2013 Feb;21(2):348-57. doi: 10.1038/mt.2012.204. Epub 2012 Sep 25. Erratum in: Mol Ther. 2013 Apr;21(4):913. Grau, Marta C [corrected to Compte, Marta].

21.

What new immunotherapeutic techniques are currently being investigated for the treatment of melanoma?

Donnelly OG, Melcher AA, Vile RG, Pulido J.

Immunotherapy. 2012 Aug;4(8):749-51. doi: 10.2217/imt.12.65. No abstract available.

22.

Oncolytic Vaccinia virus and radiotherapy in head and neck cancer.

Mansfield D, Pencavel T, Kyula JN, Zaidi S, Roulstone V, Thway K, Karapanagiotou L, Khan AA, McLaughlin M, Touchefeu Y, Seth R, Melcher AA, Vile RG, Pandha HS, Harrington KJ.

Oral Oncol. 2013 Feb;49(2):108-18. doi: 10.1016/j.oraloncology.2012.07.019. Epub 2012 Aug 25.

PMID:
22925693
23.

Reovirus exerts potent oncolytic effects in head and neck cancer cell lines that are independent of signalling in the EGFR pathway.

Twigger K, Roulstone V, Kyula J, Karapanagiotou EM, Syrigos KN, Morgan R, White C, Bhide S, Nuovo G, Coffey M, Thompson B, Jebar A, Errington F, Melcher AA, Vile RG, Pandha HS, Harrington KJ.

BMC Cancer. 2012 Aug 24;12:368. doi: 10.1186/1471-2407-12-368.

24.

Synergistic cytotoxicity of oncolytic reovirus in combination with cisplatin-paclitaxel doublet chemotherapy.

Roulstone V, Twigger K, Zaidi S, Pencavel T, Kyula JN, White C, McLaughlin M, Seth R, Karapanagiotou EM, Mansfield D, Coffey M, Nuovo G, Vile RG, Pandha HS, Melcher AA, Harrington KJ.

Gene Ther. 2013 May;20(5):521-8. doi: 10.1038/gt.2012.68. Epub 2012 Aug 16.

25.

Phase II trial of intravenous administration of Reolysin(®) (Reovirus Serotype-3-dearing Strain) in patients with metastatic melanoma.

Galanis E, Markovic SN, Suman VJ, Nuovo GJ, Vile RG, Kottke TJ, Nevala WK, Thompson MA, Lewis JE, Rumilla KM, Roulstone V, Harrington K, Linette GP, Maples WJ, Coffey M, Zwiebel J, Kendra K.

Mol Ther. 2012 Oct;20(10):1998-2003. doi: 10.1038/mt.2012.146. Epub 2012 Aug 7.

26.

Systemic combination virotherapy for melanoma with tumor antigen-expressing vesicular stomatitis virus and adoptive T-cell transfer.

Rommelfanger DM, Wongthida P, Diaz RM, Kaluza KM, Thompson JM, Kottke TJ, Vile RG.

Cancer Res. 2012 Sep 15;72(18):4753-64. doi: 10.1158/0008-5472.CAN-12-0600. Epub 2012 Jul 26.

27.

Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies.

Karapanagiotou EM, Roulstone V, Twigger K, Ball M, Tanay M, Nutting C, Newbold K, Gore ME, Larkin J, Syrigos KN, Coffey M, Thompson B, Mettinger K, Vile RG, Pandha HS, Hall GD, Melcher AA, Chester J, Harrington KJ.

Clin Cancer Res. 2012 Apr 1;18(7):2080-9. doi: 10.1158/1078-0432.CCR-11-2181. Epub 2012 Feb 7.

28.

Adoptive T cell therapy promotes the emergence of genomically altered tumor escape variants.

Kaluza KM, Thompson JM, Kottke TJ, Flynn Gilmer HC, Knutson DL, Vile RG.

Int J Cancer. 2012 Aug 15;131(4):844-54. doi: 10.1002/ijc.26447. Epub 2011 Nov 30.

29.

Dynamics of melanoma tumor therapy with vesicular stomatitis virus: explaining the variability in outcomes using mathematical modeling.

Rommelfanger DM, Offord CP, Dev J, Bajzer Z, Vile RG, Dingli D.

Gene Ther. 2012 May;19(5):543-9. doi: 10.1038/gt.2011.132. Epub 2011 Sep 15.

30.

Immune recruitment and therapeutic synergy: keys to optimizing oncolytic viral therapy?

Naik JD, Twelves CJ, Selby PJ, Vile RG, Chester JD.

Clin Cancer Res. 2011 Jul 1;17(13):4214-24. doi: 10.1158/1078-0432.CCR-10-2848. Epub 2011 May 16.

31.

Internalization of oncolytic reovirus by human dendritic cell carriers protects the virus from neutralization.

Ilett EJ, Bárcena M, Errington-Mais F, Griffin S, Harrington KJ, Pandha HS, Coffey M, Selby PJ, Limpens RW, Mommaas M, Hoeben RC, Vile RG, Melcher AA.

Clin Cancer Res. 2011 May 1;17(9):2767-76. doi: 10.1158/1078-0432.CCR-10-3266. Epub 2011 Mar 9.

32.

Therapeutic effect of sodium iodide symporter gene therapy combined with external beam radiotherapy and targeted drugs that inhibit DNA repair.

Hingorani M, White CL, Zaidi S, Pandha HS, Melcher AA, Bhide SA, Nutting CM, Syrigos KN, Vile RG, Vassaux G, Harrington KJ.

Mol Ther. 2010 Sep;18(9):1599-605. doi: 10.1038/mt.2010.120. Epub 2010 Jun 29.

33.

Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers.

Harrington KJ, Karapanagiotou EM, Roulstone V, Twigger KR, White CL, Vidal L, Beirne D, Prestwich R, Newbold K, Ahmed M, Thway K, Nutting CM, Coffey M, Harris D, Vile RG, Pandha HS, Debono JS, Melcher AA.

Clin Cancer Res. 2010 Jun 1;16(11):3067-77. doi: 10.1158/1078-0432.CCR-10-0054. Epub 2010 May 18.

34.

Retargeted adenoviral cancer gene therapy for tumour cells overexpressing epidermal growth factor receptor or urokinase-type plasminogen activator receptor.

Harvey TJ, Burdon D, Steele L, Ingram N, Hall GD, Selby PJ, Vile RG, Cooper PA, Shnyder SD, Chester JD.

Gene Ther. 2010 Aug;17(8):1000-10. doi: 10.1038/gt.2010.45. Epub 2010 Apr 22.

35.

Clinical trials with oncolytic reovirus: moving beyond phase I into combinations with standard therapeutics.

Harrington KJ, Vile RG, Melcher A, Chester J, Pandha HS.

Cytokine Growth Factor Rev. 2010 Apr-Jun;21(2-3):91-8. doi: 10.1016/j.cytogfr.2010.02.006. Epub 2010 Mar 12. Review.

36.

Immunology and gene therapy: shoulder to shoulder into the fray.

Smerdou C, Ochoa C, Quetglas JI, Fontanellas A, Gonzalez-Aseguinolaza G, Vile RG, Melero I.

Mol Ther. 2010 Mar;18(3):456-9. doi: 10.1038/mt.2010.7. No abstract available.

37.

More questions than answers: a call for a moratorium on the use of intravitreal infliximab outside of a well-designed trial.

Pulido JS, Pulido JE, Michet CJ, Vile RG.

Retina. 2010 Jan;30(1):1-5. doi: 10.1097/IAE.0b013e3181cde727. No abstract available.

38.

Interference of CD40L-mediated tumor immunotherapy by oncolytic vesicular stomatitis virus.

Galivo F, Diaz RM, Thanarajasingam U, Jevremovic D, Wongthida P, Thompson J, Kottke T, Barber GN, Melcher A, Vile RG.

Hum Gene Ther. 2010 Apr;21(4):439-50. doi: 10.1089/hum.2009.143.

39.

Safety studies on intrahepatic or intratumoral injection of oncolytic vesicular stomatitis virus expressing interferon-beta in rodents and nonhuman primates.

Jenks N, Myers R, Greiner SM, Thompson J, Mader EK, Greenslade A, Griesmann GE, Federspiel MJ, Rakela J, Borad MJ, Vile RG, Barber GN, Meier TR, Blanco MC, Carlson SK, Russell SJ, Peng KW.

Hum Gene Ther. 2010 Apr;21(4):451-62. doi: 10.1089/hum.2009.111.

40.

Expression of IFN-beta enhances both efficacy and safety of oncolytic vesicular stomatitis virus for therapy of mesothelioma.

Willmon CL, Saloura V, Fridlender ZG, Wongthida P, Diaz RM, Thompson J, Kottke T, Federspiel M, Barber G, Albelda SM, Vile RG.

Cancer Res. 2009 Oct 1;69(19):7713-20. doi: 10.1158/0008-5472.CAN-09-1013. Epub 2009 Sep 22.

41.

Antitumor immunity can be uncoupled from autoimmunity following heat shock protein 70-mediated inflammatory killing of normal pancreas.

Kottke T, Pulido J, Thompson J, Sanchez-Perez L, Chong H, Calderwood SK, Selby P, Harrington K, Strome SE, Melcher A, Vile RG.

Cancer Res. 2009 Oct 1;69(19):7767-74. doi: 10.1158/0008-5472.CAN-09-1597. Epub 2009 Sep 8.

42.

Reciprocal human dendritic cell-natural killer cell interactions induce antitumor activity following tumor cell infection by oncolytic reovirus.

Prestwich RJ, Errington F, Steele LP, Ilett EJ, Morgan RS, Harrington KJ, Pandha HS, Selby PJ, Vile RG, Melcher AA.

J Immunol. 2009 Oct 1;183(7):4312-21. doi: 10.4049/jimmunol.0901074. Epub 2009 Sep 4.

43.

Evaluation of an attenuated vesicular stomatitis virus vector expressing interferon-beta for use in malignant pleural mesothelioma: heterogeneity in interferon responsiveness defines potential efficacy.

Saloura V, Wang LC, Fridlender ZG, Sun J, Cheng G, Kapoor V, Sterman DH, Harty RN, Okumura A, Barber GN, Vile RG, Federspiel MJ, Russell SJ, Litzky L, Albelda SM.

Hum Gene Ther. 2010 Jan;21(1):51-64. doi: 10.1089/hum.2009.088.

44.

The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon.

Prestwich RJ, Errington F, Diaz RM, Pandha HS, Harrington KJ, Melcher AA, Vile RG.

Hum Gene Ther. 2009 Oct;20(10):1119-32. doi: 10.1089/hum.2009.135. Review.

45.

Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication.

Prestwich RJ, Ilett EJ, Errington F, Diaz RM, Steele LP, Kottke T, Thompson J, Galivo F, Harrington KJ, Pandha HS, Selby PJ, Vile RG, Melcher AA.

Clin Cancer Res. 2009 Jul 1;15(13):4374-4381. doi: 10.1158/1078-0432.CCR-09-0334. Epub 2009 Jun 9.

46.

Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity.

Ilett EJ, Prestwich RJ, Kottke T, Errington F, Thompson JM, Harrington KJ, Pandha HS, Coffey M, Selby PJ, Vile RG, Melcher AA.

Gene Ther. 2009 May;16(5):689-99. doi: 10.1038/gt.2009.29. Epub 2009 Mar 12.

47.

Metastatic malignant melanoma.

Markovic SN, Erickson LA, Flotte TJ, Kottschade LA, McWilliams RR, Jakub JW, Farley DR, Tran NV, Schild SE, Olivier KR, Vuk-Pavlovic S, Sekulic A, Weenig RH, Pulido JS, Quevedo JF, Vile RG, Wiseman GA, Stoian I, Pittelkow MR; Melanoma Study Group of the Mayo Clinic Cancer Center.

G Ital Dermatol Venereol. 2009 Feb;144(1):1-26. Review.

PMID:
19218908
48.

Improved systemic delivery of oncolytic reovirus to established tumors using preconditioning with cyclophosphamide-mediated Treg modulation and interleukin-2.

Kottke T, Thompson J, Diaz RM, Pulido J, Willmon C, Coffey M, Selby P, Melcher A, Harrington K, Vile RG.

Clin Cancer Res. 2009 Jan 15;15(2):561-9. doi: 10.1158/1078-0432.CCR-08-1688.

49.

Inhibition of repair of radiation-induced DNA damage enhances gene expression from replication-defective adenoviral vectors.

Hingorani M, White CL, Merron A, Peerlinck I, Gore ME, Slade A, Scott SD, Nutting CM, Pandha HS, Melcher AA, Vile RG, Vassaux G, Harrington KJ.

Cancer Res. 2008 Dec 1;68(23):9771-8. doi: 10.1158/0008-5472.CAN-08-1911.

50.

Tumor infection by oncolytic reovirus primes adaptive antitumor immunity.

Prestwich RJ, Errington F, Ilett EJ, Morgan RS, Scott KJ, Kottke T, Thompson J, Morrison EE, Harrington KJ, Pandha HS, Selby PJ, Vile RG, Melcher AA.

Clin Cancer Res. 2008 Nov 15;14(22):7358-66. doi: 10.1158/1078-0432.CCR-08-0831.

Supplemental Content

Support Center